CAM
CRL icon

Claret Asset Management’s Charles River Laboratories CRL Stock Holding History

Claret Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Sell
1,000
-525
-34% -$93.5K 0.02% 329
2026
Q1 		$263K Hold
1,525
– – 0.03% 230
2025
Q4 		$304K Sell
1,525
-3
-0.2% -$544 0.04% 175
2025
Q3 		$239K Sell
1,528
-22
-1% -$3.49K 0.03% 293
2025
Q2 		$235K Buy
+1,550
New +$207K 0.03% 237

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Claret Asset Management's CRL Position: Q2 2026 in Review

Claret Asset Management reduced its Charles River Laboratories (CRL) stake by 34% in Q2 2026, selling an estimated $93.5K and leaving 1,000 shares worth $227K. The position accounts for 0.02% of the portfolio, ranked #329.

Claret Asset Management first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. The position peaked at $304K in Q4 2025. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Claret Asset Management held 1,000 shares of Charles River Laboratories worth $227K as of Q2 2026.
  • Claret Asset Management sold 525 Charles River Laboratories shares in Q2 2026, an estimated $93.5K.
  • Charles River Laboratories made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #329 holding.
  • Claret Asset Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • Claret Asset Management's Charles River Laboratories position peaked at $304K in Q4 2025.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.